Elicio Therapeutics, Inc. (ELTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
451 D Street
Boston, MA 02210
United States of America (the)
Phone
857-209-0050
Website
Sector
Healthcare
Industry
Biotechnology
Employees
33
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Robert T. Connelly | Chief Executive Officer, President & Director | 980,700 | 1960 |
| Allen Richard Nissenson FACP | Founder & Independent Director | 52,500 | 1947 |
| Peter DeMuth | Chief Scientific Officer | 648,600 | 1987 |
| Preetam Shah | Chief Strategy & Financial Officer and Treasurer | 687,077 | 1973 |
| Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer | 750,000 | 1966 |
| Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | 0 | N/A |
| Esther Welkowsky | Senior Vice President of Clinical Development | 0 | N/A |
| Megan C. Filoon | General Counsel, Secretary & Compliance Officer | 0 | N/A |
| Joy Seymour | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Marc J. Wolfgang | Chief Technology Officer | 0 | N/A |
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.